Pharmaceutical - Pharmaceutical, North America, Novartis

Filter

1 to 25 of 50 results

US FDA advisory panel votes against approval of Novartis’ AHF drug

US FDA advisory panel votes against approval of Novartis’ AHF drug

28-03-2014

The US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee yesterday voted…

Cardio-vascularNorth AmericaNovartisPharmaceuticalReasanzRegulationserelaxinUSA

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

10-01-2014

Swiss drug major Novartis faced two problems yesterday, when the Japanese Ministry of Health Labor and…

Asia-PacificCardio-vascularDiovanExjadeHematologyLegalMarkets & MarketingNorth AmericaNovartisPharmaceuticalUSA

Retrophin to acquire Kyalin Biosciences; in-licenses Syntocinon

13-12-2013

In a second takeover bid within a matter of months, USA-based Retrophin announced that it will acquire…

Kyalin BiosciencesLicensingMergers & AcquisitionsNeurologicalNorth AmericaNovartisPharmaceuticalRetrophinSyntocinonWomen's Health

ASH 2013: Meeting highlights from Takeda, Roche, Novartis and Gilead

ASH 2013: Meeting highlights from Takeda, Roche, Novartis and Gilead

09-12-2013

The 55th American Society of Hematology (ASH) meeting began in New Orleans on Saturday with a host of…

Gilead SciencesNorth AmericaNovartisPharmaceuticalResearchRocheTakeda Pharmaceuticals

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms

19-11-2013

Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

Novartis third quarter results driven by strong sales despite generic competition

Novartis third quarter results driven by strong sales despite generic competition

22-10-2013

Novartis has announced strong sales performance in its third quarter results, released today.

DiovanEuropeFinancialNorth AmericaNovartisPharmaceuticalSandozZometa

US NIH trials flu vaccines from Sanofi and Novartis

US NIH trials flu vaccines from Sanofi and Novartis

19-09-2013

The US National Institutes of Health has begun testing an H7N9 avian influenza vaccine candidate in humans.

GlaxoSmithKlineHealthcareNorth AmericaNovartisPharmaceuticalSanofi PasteurVaccines

Mixed US views on Gilenya, Aubagio and Tecfidera as breakthrough MS drugs

03-09-2013

More than half of surveyed neurologists consider US biotech firm Biogen Idec's (Nasdaq: BIIB) Tecfidera…

AubagioBiogen IdecGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalPricingSanofiTecfidera

FDA investigating rare brain infection in patient taking Gilenya

30-08-2013

In a safety communication issued on Thursday (August 29), the US Food and Drug Administration is alerting…

GilenyaNeurologicalNorth AmericaNovartisPharmaceuticalRegulation

Novartis gains breakthrough therapy designation for sIBM drug from US FDA

20-08-2013

Swiss drug major Novartis (NOVN: VX) has gained US Food and Drug Administration breakthrough therapy…

bimagrumabInflammatory diseasesNorth AmericaNovartisPharmaceuticalRegulation

FDA expands age indication for Menveo, quadrivalent meningococcal vaccine

02-08-2013

The US Food and Drug Administration late yesterday (August 1) approved Swiss drug major Novartis' (NOVN:…

MenveoNorth AmericaNovartisPharmaceuticalRegulationVaccines

US Appeals Court overturns Copaxone patent decision

28-07-2013

Israel-based generics giant Teva Pharmaceutical Industries ((NYSE: TEVA) said on Friday (July 26) that…

CopaxoneGenericsLegalMomenta PharmaceuticalsMylan LaboratoriesNatco PharmaNeurologicalNorth AmericaNovartisPatentsPharmaceuticalSandozTeva Pharmaceutical Industries

"Breakthrough" status from FDA for Novartis' serelaxin (RLX030) for acute heart failure

21-06-2013

The US Food and Drug Administration has granted Breakthrough Therapy designation status to RLX030 (serelaxin),…

Cardio-vascularNorth AmericaNovartisPharmaceuticalRegulationRLX030serelaxin

Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent

19-06-2013

USA-based Actavis (NYSE: ACT), itself predominantly a generic drug marketer, and Japan's Kissei Pharmaceutical…

ActavisGenericsHetero GroupMen's HealthNorth AmericaNovartisPatentsPharmaceuticalRapaflo CapsulesSandoz

Novartis charged with paying "kickbacks" to US doctors

29-04-2013

The US Department of Justice announced last Friday (April 26) that the government has filed a second…

LegalMarkets & MarketingNorth AmericaNovartisPharmaceutical

US FDA approves Alcon's Simbrinza, a fixed-combination therapy for glaucoma

22-04-2013

Swiss drug major Novartis' (NOVN: VX) eye care division Alcon on Friday (April 19) received US Food and…

AlconNorth AmericaNovartisOphthalmicsPharmaceuticalRegulationSimbrinza

Sales of psoriasis drugs to be worth $7.4 billion by 2020

19-04-2013

The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

FDA approves Novartis' TOBI Podhaler and Cangene's first Botulism Antitoxin heptavalent

24-03-2013

The US Food and Drug Administration on Friday approved Swiss drug major Novartis' (NOVN: VX) TOBI Podhaler…

Antibiotics and Infectious diseasesBotulism antitoxinCangeneNorth AmericaNovartisPharmaceuticalRegulationRespiratory and PulmonaryTobi Podhaler

Novartis' LDK378 latest to receive FDA Breakthrough Therapy designation

15-03-2013

Swiss drug major Novartis (NOVN: VX) says that its investigational compound LDK378 has received Breakthrough…

LDK378North AmericaNovartisOncologyPharmaceuticalRegulation

Novartis' Zortress first drug in over a decade approved by FDA to prevent organ rejection

18-02-2013

Swiss drug major Novartis (NOVN: VX) said on Friday that the US Food and Drug Administration has approved…

ImmunologicalsNorth AmericaNovartisPharmaceuticalRegulationZortress

Novartis/Incyte's Jakafi will be greatest growth driver in myelofibrosis market

31-01-2013

Through 2021, the continued uptake of Novartis (NOVN: VX)/Incyte's (Nasdaq: INCY) recently launched JAK-2…

BiotechnologyCYT387EuropeGilead SciencesIncyteJakafiMarkets & MarketingNorth AmericaNovartisOncologyPharmaceuticalYM Biosciences

FDA approves three Takeda diabetes drugs; expands use of Novartis' Gleevec and Pfizer's Prevnar 13

28-01-2013

In what was a busy news day for the US Food and Drug Administration, the agency on Friday approved three…

alogliptinDiabetesFuriex PharmaceuticalsGleevecKazanoLiovelNesinaNorth AmericaNovartisOncologyOseniPfizerPharmaceuticalPrevnarRegulationTakeda PharmaceuticalsVaccines

FDA clears new use for Roche's Avastin and Novartis' Exjade

25-01-2013

The US Food and Drug Administration has approved a new use for Swiss drug major Roche's (ROG: SIX) US…

AvastinBiotechnologyExjadeGenentechNorth AmericaNovartisOncologyPharmaceuticalRegulationRoche

US FDA approvals for Signifor, raxibacumab and Iclusig

17-12-2012

In a flurry of activity from the US Food and Drug Administration on Friday, the agency - which looks…

Antibiotics and Infectious diseasesAriad PharmaceuticalsGlaxoSmithKlineIclusigNorth AmericaNovartisOncologyPharmaceuticalRare diseasesraxibacumabRegulationSignifor

1 to 25 of 50 results

Back to top